Drugs / DAOIB
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06467539 Background | Jun 2024 → May 2027 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Chang Gung Memorial Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DAOIB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06467539 ↗ |
| Route | Oral | “oral, for 24 weeks” NCT06467539 ↗ |